PlainPharmaWatch

CMS Open Payments · Program Year 2024

Bayer Puerto Rico Inc.

Bayer Puerto Rico Inc. reported $18,263.35 across General Payments, Research, and Ownership to 821 physicians and teaching hospitals across 821 transactions.

$18.3K
All-tracks total
821
Transactions
821
Recipients
+$2.6K
General Payments vs PY2023

Bayer Puerto Rico Inc. reported $18,263.35 across all CMS Open Payments tracks (General + Research + Ownership) to 821 physicians and teaching hospitals in Program Year 2024 - ranking #1546 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $18,263.35, averaging $22.25 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer bayer-puerto-rico-inc Bayer Puerto Rico Inc.

$18.3K · #1546/1,925 · 0.0% industry · PY2024

  • TOT $18.3K
  • RANK #1546
  • SHARE 0.0%
  • TXN 821
  • RCP 821
  • CAT 1
  • GEN $18.3K
  • ΔGEN +$2.6K
  • TOP1 2.1%
  • PY 2024

Nearest volume peer: Ostial Corporation ($18.2K)

Lumos Diagnostics, Inc.$18.5KBayer Puerto Rico Inc. (this)$18.3KOstial Corporation$18.2KFerring SA de CV$18.0KSolco Biomedical Corporation$18.0K
All-tracks payment totals near Bayer Puerto Rico Inc. (CMS Open Payments PY2024)

Bayer Puerto Rico Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Bayer Puerto Rico Inc.'s CMS-reported General Payments increased by $2.6K (+16.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2023: BAYER PUERTO RICO INC.PY2024: Bayer Puerto Rico Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$15.7KPY2024$18.3K
PY2023
$15,681.59
PY2024
$18,263.35

What the Data Shows for Bayer Puerto Rico Inc.

Averaging $22.25 per transaction and $22.25 per recipient, Bayer Puerto Rico Inc.'s Program Year 2024 total comes to $18,263.35 across 821 transactions and 821 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1546 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

821 transactions worth $18.3K make "Food and Beverage" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 1 types of general payments, Bayer Puerto Rico Inc.'s largest category was "Food and Beverage" at $18.3K - 100.0% of General Payments.

How Bayer Puerto Rico Inc. divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$18.3K
Payment Type Amount Transactions
Food and Beverage $18.3K 821

Recipient Concentration in General Payments

The five largest recipient relationships account for $1,549.60 (8.5%) of $18,263.35 in this company's General Payments records across 232 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Bayer Puerto Rico Inc.

The five named recipients with the highest reported General Payments from this company

Alex Gonzalez Bossolo$375.64Ada Santiago Carrion$308.12Efrain Gonzalez$289.66Stephanie Colon Lopez$288.09Eddie M Rodriguez Castro$288.09
  1. 1

    Alex Gonzalez Bossolo

    $375.64 across 17 reported transactions

  2. 2

    Ada Santiago Carrion

    $308.12 across 13 reported transactions

  3. 3

    Efrain Gonzalez

    $289.66 across 12 reported transactions

  4. 4

    Stephanie Colon Lopez

    $288.09 across 13 reported transactions

  5. 5

    Eddie M Rodriguez Castro

    $288.09 across 13 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Bayer Puerto Rico Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Bayer Puerto Rico Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Bayer Puerto Rico Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Bayer Puerto Rico Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.